ClinicalTrials.gg
CompletedNCT07948889PENG-Block-RCTUpdated Nov 19, 2026

Phrenic Nerve -Sparing Effect of Pericapsular Nerve Group Block Versus Low-Volume Interscalene Brachial Plexus Block for Analgesia Following Shoulder Surgeries

An interventional study of Ultrasound-guided Pericapsular Nerve Group (PENG) Block and Ultrasound-guided Low-Volume Interscalene Brachial Plexus Block in Postoperative Pain, Shoulder Surgery and Diphragmatic Sparing, sponsored by Zagazig University. Completed at 1 site in Egypt. Open to participants aged 21 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Zagazig University · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Registered 1 year 10 months after the study started (first participant enrolled Jan 2025, registered Nov 2026).
Updated Nov 19, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
21 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 18 studies in Pain, Postoperative by Zagazig University — 7 open to participants now, 8 under way, 1 of them phase 3. Pain, Postoperative · Zagazig University.

Enrollment
8th of 18
72 · median 65
Started
2025
with 3 others
No phase
12 of 18
6 open now
Registered
18th of 18
by date

Among the 18 studies in Pain, Postoperative by Zagazig University, this one is the 8th largest by enrollment, is one of 4 that started in 2025, is one of 12 with no phase, and was the 18th registered.

Pain, Postoperative

5,680 studies on the registry are indexed under Pain, Postoperative; 1,240 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

7 of the 18 studies in Pain, Postoperative by Zagazig University are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 675 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 328 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.

This study: 21 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Pain, Postoperative by Zagazig University, or all of them as a file.
02

Study summary

This randomized, double-blind clinical trial compared the ultrasound-guided pericapsular nerve group (PENG) block (20 mL of 0.25% bupivacaine) with low-volume interscalene brachial plexus block (ISB) (5 mL of 0.25% bupivacaine) in 72 adult patients undergoing elective unilateral shoulder surgery. The study evaluated diaphragmatic excursion via M-mode ultrasound as a measure of phrenic nerve preservation, alongside postoperative analgesic efficacy and safety.

03

Conditions studied

  • Postoperative Pain
  • Shoulder Surgery
  • Diphragmatic Sparing
  • PENG Block

Browse trials for

Keywords

  • PENG Block
  • diphragmatic sparing
  • interscalene brachial plexus block
  • ultrasound guided
  • shoulder surgery
04

Who can participate

Ages eligible
21 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

    • Inclusion Criteria:

      • Adult patients aged 21 to 60 years of both sexes.
      • (ASA) physical status I and II.
      • (BMI) \< 30 kg/m².
      • Cooperative patients scheduled for elective unilateral shoulder-level upper limb surgeries lasting less than 2 hours.
      • Written obtained.

Exclusion Criteria:

    • Patient refusal.

      • Advanced bronchopulmonary disease.
      • Known phrenic nerve pathology or peripheral neuropathy.
      • Pathological coagulopathy.
      • Infection at the injection site
      • Allergy to local anesthetics used in the trial (bupivacaine).
      • Pregnancy.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
72 participants (actual)

Study arms

  • Experimental
    Ultrasound-guided Pericapsular Nerve Group (PENG) Block

    • 36 patients received an ultrasound-guided pericapsular nerve group (PENG) block using 20 mL of 0.25% bupivacaine following the induction of general anesthesia.

    Procedure: Ultrasound-guided Pericapsular Nerve Group (PENG) Block

  • Active comparator
    Ultrasound-guided Low-Volume Interscalene Brachial Plexus Block

    • 36 patients received an ultrasound-guided low-volume interscalene brachial plexus block (ISB) using 5 mL of 0.25% bupivacaine following the induction of general anesthesia.

    Procedure: Ultrasound-guided Low-Volume Interscalene Brachial Plexus Block

Interventions

  • ProcedureUltrasound-guided Pericapsular Nerve Group (PENG) Block

    With the patient supine, the arm was abducted and externally rotated at 45°, and the skin was disinfected with Betadine. Using a high-frequency linear ultrasound probe, the humeral head, subscapularis tendon, and deltoid muscle were identified. A 22-gauge echogenic needle was advanced in-plane in a cranio-caudal direction between the deltoid and subscapularis muscles. After negative aspiration, 20 mL of 0.25% bupivacaine was injected

  • ProcedureUltrasound-guided Low-Volume Interscalene Brachial Plexus Block

    With their head toward the opposite side, the patient was placed in a supine position. Betadine was used to sterilise the neck's skin. The C7 root emerged from the C7 vertebra with no anterior tubercle when the lateral surface of the neck was exposed to a linear, high-frequency ultrasonic probe. The probe was pushed cephalad until the stop-light image appeared in order to find the C6 and C5 roots, which are located between the anterior and middle scalene muscles. A 22-gauge echogenic needle was inserted in-plane in a lateral to medial position in the interscalene groove lateral to C5-6 roots.10 Five milliliters of 0.25% bupivacaine were given while the needle stayed still following negative aspiration

06

What researchers measure

Primary outcomes

  1. Diaphragmatic Excursion

    Assessed in centimeters using M-mode ultrasonography (2-5 MHz convex probe) in the supine position as the craniocaudal displacement from baseline to the end of inspiration, and percentage reduction to grade hemidiaphragmatic paresis.

    Time frame: Baseline (before block) and at 6, 12, and 24 hours postoperatively

Secondary outcomes

  1. Postoperative Pain Intensity

    Assessed using the Numerical Rating Scale (NRS, 0-10)

    Time frame: at rest and during shoulder movement at 2, 4, 6, 8, 12, 16, and 24 hours postoperatively

  2. Duration of Analgesia

    time from block completion to first rescue analgesia request (NRS ≥ 3)

    Time frame: up to 24 hours

  3. Total Opioid Consumption

    Intraoperative fentanyl (µg) and postoperative 24-hour IV nalbuphine (mg) consumption.

    Time frame: 24 hours

07

Study locations

1 site
  • Zagazig University Hospitals
    Zagazig, Ash Sharkia, Egypt
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be shared puplicly due to patient privacy regulations and institutional ethical committee restrictions

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2025 to primary completion in Jan 2026, 12 months.

Of 2,107 non-industry interventional studies with no phase under Pain, Postoperative, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's 12 months is close to that.

Counting every sponsor, half of 2,120 studies reached it within 11 months; a quarter within 6 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2026
First posted
Nov 19, 2026
StartActual
Jan 10, 2025
Primary completionActual
Jan 10, 2026
CompletionActual
Jan 10, 2026
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07948889
Lead sponsor
Zagazig University
Responsible party
Sponsor
First posted
Nov 19, 2026
Start date
Jan 10, 2025
Primary completion
Jan 10, 2026
Completion
Jan 10, 2026
Last update
Nov 19, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion